Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30-positive cutaneous T-cell lymphoma with a generally favorable prognosis. While radiotherapy is effective, recurrence is not uncommon. Herein, we report the case of an 87-year-old man with recurrent pcALCL who achieved complete remission after bexarotene treatment, despite resistance to radiotherapy and topical steroids. This case highlights bexarotene as a promising therapeutic option for refractory pcALCL. Our experience reinforces the potential of bexarotene as a viable treatment for pcALCL, particularly in recurrent or refractory cases where conventional therapies are contraindicated or ineffective.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-10-16
DOI
https://doi.org/10.7759/cureus.94700
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report

Hidehiko Fujimura, Yu Sawada, Natsuko Saito‐Sasaki, N Shimada et al.
Cureus
Cutaneous lymphoproliferative disorders research
article

Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report

Hidehiko Fujimura, Yu Sawada, Natsuko Saito‐Sasaki, N Shimada, Hikaru Kawahara, Etsuko Okada
article en

Abstract

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30-positive cutaneous T-cell lymphoma with a generally favorable prognosis. While radiotherapy is effective, recurrence is not uncommon. Herein, we report the case of an 87-year-old man with recurrent pcALCL who achieved complete remission after bexarotene treatment, despite resistance to radiotherapy and topical steroids. This case highlights bexarotene as a promising therapeutic option for refractory pcALCL. Our experience reinforces the potential of bexarotene as a viable treatment for pcALCL, particularly in recurrent or refractory cases where conventional therapies are contraindicated or ineffective.

CureusVol. 17(10)
University of Occupational and Environmental Health Japan (JP)
Openalex Percentile: Top 50%
Cutaneous lymphoproliferative disorders research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report — Hidehiko Fujimura, Yu Sawada, et al. · Cureus (2025) | TGRS Research Map | TGRS